Intervention vs Usual Care: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.217 | 0.206 | 0.228 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.223 | 0.212 | 0.234 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00609 | -0.0216 | 0.00938 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.973 | 0.906 | 1.04 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.965 | 0.882 | 1.06 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Intervention than on Usual Care | 164 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Intervention | Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator~Collaborative Model of Primary care and Subspecialty care: Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials. | 1,193 | 5,508 | EG000 | ClinicalTrials.gov |
| Group 2 | Usual Care | Group to receive regular care | 1,223 | 5,492 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | 1 YEAR | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Improving Chronic Disease Management With Pieces | ClinicalTrials.gov |
| NCT number | NCT02587936 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes | ClinicalTrials.gov |
| Interventions | Collaborative Model of Primary care and Subspecialty care | ClinicalTrials.gov |
| Lead sponsor | University of Texas Southwestern Medical Center | ClinicalTrials.gov |
| Results first posted | 2023-12-20 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02587936?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.